Synergistic anti-cancer effects of brusatol and trastuzumab (HER2 targeting agent) were reported in HER2 positive BC and associated with induction of reactive oxygen species (ROS) production and apoptosis [83]. This evidence concerns the gene ERBB2 and breast cancer.